Skip to main content

Table 3 Competing risk regression to evaluate the effect of selected covariates on prostate cancer incidence

From: Cholesterol and prostate cancer risk: a long-term prospective cohort study

  Full-time follow-up period, n = 1997 Restricted to more than 20 year of follow-up, n = 1520
  Univariate analyses Multivariate analysis Multivariate analysis
  SHR (95 % CI) P-value SHR (95 % CI) P-value SHR (95 % CI) P-value
Cholesterol (mmol/l)   <0.001*   <0.001*   0.01*
 Q1 (2.7 – 5.8) 2.15 (1.44–3.22) <0.001 2.00 (1.32–3.03) 0.001 2.00 (1.20–3.34) <0.01
 (5.9 – 6.6) 1.36 (0.88–2.09) 0.17 1.29 (0.83–2.00) 0.26 1.46 (0.86–2.48) 0.16
 Q3 (6.7 – 7.4) 1.42 (0.92–2.21) 0.12 1.36 (0.87–2.12) 0.17 1.55 (0.90–2.66) 0.11
 Q4 (7.5 – 15.4) 1   1   1  
Age at inclusion (years)   0.48*   0.40*   0.36*
 < 45 1   1   1  
 45–49 0.84 (0.58–1.20) 0.33 0.92 (0.64–1.32) 0.66 0.97 (0.66–1.43) 0.89
 50–54 0.87 (0.60–1.25) 0.45 1.09 (0.73–1.62) 0.67 0.86 (0.54–1.35) 0.51
 55+ 0.85 (0.57–1.27) 0.43 1.15 (0.75–1.79) 0.52 0.80 (0.46–1.40) 0.44
Smoking       
 Never 1   1   1  
 Ever 0.75 (0.56–1.01) 0.06 0.79 (0.59–1.07) 0.12 0.81 (0.58–1.14) 0.22
Physical fitness (kJ/kg)   <0.001*   0.01*   0.12*
 T1 (21.1 – 118.6) 1   1   1  
 T2 (118.7 – 161.2) 1.38 (0.96–1.98) 0.08 1.43 (0.98–2.07) 0.06 1.27 (0.82–1.99) 0.29
 T3 (161.3 – 515.9) 1.76 (1.25–2.48) <0.01 1.68 (1.14–2.47) 0.01 1.43 (0.92–2.22) 0.11
Body mass index (kg/m2)       
 <25 1   1   1  
 ≥ 25 0.66 (0.49–0.89) <0.01 0.69 (0.52–0.93) 0.01 0.62 (0.44–0.88) <0.01
Systolic blood pressure (mmHg)   0.59*   0.55*   0.41*
 Q1 (88 – 118) 1   1   1  
 Q2 (120 – 128) 0.85 (0.59–1.23) 0.39 0.89 (0.62–1.28) 0.53 1.00 (0.66–1.51) 0.99
 Q3 (130 – 140) 0.83 (0.57–1.22) 0.35 0.96 (0.65–1.40) 0.83 1.06 (0.68–1.65) 0.79
 Q4 (142 – 220) 0.92 (0.64–1.32) 0.63 1.13 (0.78–1.65) 0.52 1.22 (0.78–1.93) 0.37
  1. SHR sub-distribution hazard ratios, CI confidence interval, Q1 - Q4 quartiles, T1 - T3 tertiles
  2. *P-value from test for trend across ordered categories